Biomednewsbreaks - Calidi Biotherapeutics Inc. (NYSE American: CLDI) Announces $3.9 Million Registered Direct Offering And Private Placement
Calidi Biotherapeutics (NYSE American: CLDI) , a clinical-stage biotechnology company advancing targeted immunotherapies, has entered into a securiti ...
Calidi prices 3.33M shares at 65c in registered direct offering
Biotherapeutics has entered into a definitive securities purchase agreement with a single institutional investor for the purchase ...
Calidi Biotherapeutics Announces Pricing of $3.9 Million Registered Direct Offering and Concurrent Private Placement
Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI) (“Calidi” or the “Company”), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, today announced that it ...
Q4 2024 Corvus Pharmaceuticals Inc Earnings Call
Thank you for standing by and welcome to the Corvus Pharmaceuticals fourth-quarter and full-year 2024 business update and financial results conference call. (Operator Instructions) It is now my ...
Corvus Pharmaceuticals outlines clinical milestones for soquelitinib in 2025
Discover Corvus Pharmaceuticals' Q4 2024 earnings insights, highlighting soquelitinib's trial progress, upcoming milestones for 2025, and robust ...